Korea's firstIntegrated Stem Cell Bank
Bio Insurance
Korea's firstIntegrated Stem Cell Bank
Bio Insurance
Korea's firstIntegrated Stem Cell Bank
Bio Insurance
Korea's firstIntegrated Stem Cell Bank
Bio Insurance
Korea's firstIntegrated Stem Cell Bank
Bio Insurance
Global CHA Network
| Type | Cell type | Product | Indication | predecessor award | Phase I clinical trial | Phase II clinical trial | Clinical III Award | Applied technology |
|---|---|---|---|---|---|---|---|---|
| Autologous |
Immunocytes | CBT101* |
solid cancer (Recurrent Glioblastoma) |
NK-FF | ||||
| Allogenic | Immunocytes | Allo-NK | solid cancer | NK-AFF | ||||
| Neuropathic cells |
FMD-NPC | Parkinson’s Disease (PD) |
EP-NPC | |||||
| Stem cell | CordSTEM-DD | Disk | MSC-CORD | |||||
| CordSTEM-ST | Stroke | |||||||
| CordSTEM-AS | Asherman's syndrome |
|||||||
| CordSTEM-ARDS | Severe respiratory disease |
|||||||
| ES-MSC | premature ovarian failure |
H-ES | ||||||
| hESC-RPE | Macular Degeneration (AMD) |
Astellas(US) Partnership |
||||||
| hESC-RPE | Stargard's disease |
| *U.S. FDA designates rare drug for recurrent malignant neuropods (2020.9) | CHA Biotech program | Partnered program |
